» Articles » PMID: 15223826

Encapsulated Cell-based Intraocular Delivery of Ciliary Neurotrophic Factor in Normal Rabbit: Dose-dependent Effects on ERG and Retinal Histology

Overview
Specialty Ophthalmology
Date 2004 Jun 30
PMID 15223826
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: ERG and histologic changes were investigated in normal rabbits after intravitreal implantation of encapsulated cell technology (ECT) devices releasing ciliary neurotrophic factor (CNTF).

Methods: Fifteen adult New Zealand White albino rabbits had ECT devices secreting CNTF at 22, 5, or 0 ng/d implanted in the superior temporal quadrant of the left eye. The low dose has been shown to produce substantial rescue of photoreceptors in the rcd1 canine model of retinal degeneration. Right eyes were untreated. Ganzfeld dark- and light-adapted ERGs and clinical observations were performed at 5, 15, and 25 days after implantation. Rod a-waves and rod and cone b-waves and outer nuclear layer (ONL) morphology were evaluated at 25 days.

Results: Clinical examination showed minimal changes in a few CNTF-treated eyes, including vitreous membranes and engorgement of iris vessels at day 25. Retinas appeared normal. CNTF did not significantly affect the rod a- or b-waves, although the b-wave amplitude tended to be larger in CNTF-treated retinas at low flash intensities. The cone b-wave amplitude was significantly reduced in high-dose eyes at some flash intensities. The ONL area in high-dose eyes was significantly greater because of increased thickness than in fellow retinas. ONL cell size was significantly increased, and staining density decreased in CNTF-treated retinas.

Conclusions: CNTF, given by intravitreal ECT device at doses that protect photoreceptors in a canine model of retinal degeneration (5 ng/d), did not adversely affect either rod or cone ERG function of normal rabbit retina. The cone ERG was more sensitive to suppression being reduced, at low flash intensities, by 22 ng/d. Dose-related changes in the ONL and photoreceptor cell nuclei did not represent a toxic effect, because they were not associated with deficits in the rod ERG over a broad range of intensities.

Citing Articles

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement.

Goldberg J, Beykin G, Satterfield K, Nunez M, Lam B, Albini T Ophthalmol Sci. 2023; 3(3):100298.

PMID: 37197702 PMC: 10183667. DOI: 10.1016/j.xops.2023.100298.


Ciliary neurotrophic factor-mediated neuroprotection involves enhanced glycolysis and anabolism in degenerating mouse retinas.

Rhee K, Wang Y, Hoeve J, Stiles L, Nguyen T, Zhang X Nat Commun. 2022; 13(1):7037.

PMID: 36396639 PMC: 9672129. DOI: 10.1038/s41467-022-34443-x.


Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies.

Jemni-Damer N, Guedan-Duran A, Fuentes-Andion M, Serrano-Bengoechea N, Alfageme-Lopez N, Armada-Maresca F Front Bioeng Biotechnol. 2020; 8:588014.

PMID: 33363125 PMC: 7758210. DOI: 10.3389/fbioe.2020.588014.


Antioxidant and Biological Properties of Mesenchymal Cells Used for Therapy in Retinitis Pigmentosa.

Limoli P, Vingolo E, Limoli C, Nebbioso M Antioxidants (Basel). 2020; 9(10).

PMID: 33066211 PMC: 7602011. DOI: 10.3390/antiox9100983.


Characterization, Stability, and in Vivo Efficacy Studies of Recombinant Human CNTF and Its Permeation into the Neural Retina in ex Vivo Organotypic Retinal Explant Culture Models.

Itkonen J, Annala A, Tavakoli S, Arango-Gonzalez B, Ueffing M, Toropainen E Pharmaceutics. 2020; 12(7).

PMID: 32629980 PMC: 7408322. DOI: 10.3390/pharmaceutics12070611.